CN1148189C - 作为tnf抑制剂和pdc-iv抑制剂的喹啉甲酰胺类化合物 - Google Patents

作为tnf抑制剂和pdc-iv抑制剂的喹啉甲酰胺类化合物 Download PDF

Info

Publication number
CN1148189C
CN1148189C CNB97194735XA CN97194735A CN1148189C CN 1148189 C CN1148189 C CN 1148189C CN B97194735X A CNB97194735X A CN B97194735XA CN 97194735 A CN97194735 A CN 97194735A CN 1148189 C CN1148189 C CN 1148189C
Authority
CN
China
Prior art keywords
methanamide
dichloropyridine
methoxy quinoline
alkyl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB97194735XA
Other languages
English (en)
Chinese (zh)
Other versions
CN1219131A (zh
Inventor
Hj
H·J·戴克
J·G·蒙塔那
C·洛
H·J·肯达尔
V·M·萨宾
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Darwin Discovery Ltd
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9610506.9A external-priority patent/GB9610506D0/en
Priority claimed from GBGB9623234.3A external-priority patent/GB9623234D0/en
Priority claimed from GBGB9626883.4A external-priority patent/GB9626883D0/en
Priority claimed from GBGB9708072.5A external-priority patent/GB9708072D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of CN1219131A publication Critical patent/CN1219131A/zh
Application granted granted Critical
Publication of CN1148189C publication Critical patent/CN1148189C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
CNB97194735XA 1996-05-20 1997-05-20 作为tnf抑制剂和pdc-iv抑制剂的喹啉甲酰胺类化合物 Expired - Fee Related CN1148189C (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GBGB9610506.9A GB9610506D0 (en) 1996-05-20 1996-05-20 Novel compounds
GB9610506.9 1996-05-20
GB9623234.3 1996-11-07
GBGB9623234.3A GB9623234D0 (en) 1996-11-07 1996-11-07 Novel compounds
GBGB9626883.4A GB9626883D0 (en) 1996-12-24 1996-12-24 Compounds
GB9626883.4 1996-12-24
GB9708072.5 1997-04-22
GBGB9708072.5A GB9708072D0 (en) 1997-04-22 1997-04-22 Compounds

Publications (2)

Publication Number Publication Date
CN1219131A CN1219131A (zh) 1999-06-09
CN1148189C true CN1148189C (zh) 2004-05-05

Family

ID=27451451

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB97194735XA Expired - Fee Related CN1148189C (zh) 1996-05-20 1997-05-20 作为tnf抑制剂和pdc-iv抑制剂的喹啉甲酰胺类化合物

Country Status (19)

Country Link
US (1) US5804588A (2)
EP (1) EP0952832B1 (2)
JP (1) JP2000510865A (2)
KR (1) KR20000065219A (2)
CN (1) CN1148189C (2)
AT (1) ATE406163T1 (2)
AU (1) AU722472B2 (2)
BR (1) BR9709015A (2)
CA (1) CA2252531A1 (2)
CZ (1) CZ296163B6 (2)
DE (1) DE69738949D1 (2)
IL (1) IL126557A (2)
NO (1) NO312099B1 (2)
NZ (1) NZ332341A (2)
PL (1) PL329922A1 (2)
RU (1) RU2170730C2 (2)
SK (1) SK283162B6 (2)
TR (1) TR199802385T2 (2)
WO (1) WO1997044036A1 (2)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE273958T1 (de) * 1995-10-16 2004-09-15 Fujisawa Pharmaceutical Co Heterocyclische verbindungen als h+-atpasen
GB9712761D0 (en) * 1997-06-17 1997-08-20 Chiroscience Ltd Quinolines and their therapeutic use
GB9824160D0 (en) * 1998-11-04 1998-12-30 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
US6262070B1 (en) 1998-11-04 2001-07-17 Darwin Discovery Ltd. Heterocyclic compounds and their therapeutic use
EP1212089B1 (en) * 1999-08-21 2006-03-22 ALTANA Pharma AG Synergistic combination of roflumilast and salmeterol
WO2001032658A1 (en) * 1999-11-02 2001-05-10 Ajinomoto Co., Inc. Polyazanaphthalene compound and medicinal use thereof
JP4603646B2 (ja) * 1999-11-15 2010-12-22 富士フイルムファインケミカルズ株式会社 新規なジピリジル誘導体
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
GB0003256D0 (en) * 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
DE10035928A1 (de) * 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
WO2002012189A1 (en) * 2000-08-09 2002-02-14 Mitsubishi Pharma Corporation Fused bicyclic amide compounds and medicinal use thereof
US6953774B2 (en) 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation
JP2002300373A (ja) * 2001-03-30 2002-10-11 Minolta Co Ltd 画像処理方法、画像処理装置、記録媒体及びプログラム
ES2427930T3 (es) 2001-05-23 2013-11-04 Mitsubishi Tanabe Pharma Corporation Composición terapéutica para el tratamiento regenerativo de enfermedades de los cartílagos
KR20040007596A (ko) * 2001-05-23 2004-01-24 다나베 세이야꾸 가부시키가이샤 골절 치료 촉진용 조성물
US7501516B2 (en) 2001-07-16 2009-03-10 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
DE60208808T2 (de) * 2001-08-15 2006-11-02 E.I. Dupont De Nemours And Co., Wilmington Mit heterocyclen ortho-substituierte aryl amide zur bekämpfung wirbelloser schädlinge
PT1463493E (pt) 2001-12-14 2008-01-04 Serono Lab Método para induzir a ovulação utilizando um modulador de nível camp não polipeptídico
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
SE0200920D0 (sv) * 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
ES2195785B1 (es) * 2002-05-16 2005-03-16 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
AU2002950217A0 (en) 2002-07-16 2002-09-12 Prana Biotechnology Limited 8- Hydroxy Quinoline Derivatives
ES2211344B1 (es) * 2002-12-26 2005-10-01 Almirall Prodesfarma, S.A. Nuevos derivados de piridazin-3(2h)-ona.
TWI324150B (en) * 2003-02-28 2010-05-01 Novartis Ag Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salt
MXPA05010373A (es) 2003-04-01 2005-12-05 Applied Research Systems Inhibidores de fosfodiesterasas en infertilidad.
PE20050211A1 (es) * 2003-04-02 2005-04-27 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
TW200507829A (en) * 2003-05-29 2005-03-01 Astrazeneca Ab New combination
EP1644042A1 (en) * 2003-05-29 2006-04-12 AstraZeneca AB A pharmaceutical composition containing a p2x7 receptor antagonist and methotrexate
WO2004105797A1 (en) * 2003-05-29 2004-12-09 Astrazeneca Ab A pharmaceutical composition comprising a p2x7 antagonist and sulfasalazine
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (sv) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0302192D0 (sv) * 2003-08-08 2003-08-08 Astrazeneca Ab Novel compounds
CN1878765A (zh) * 2003-09-15 2006-12-13 先灵公司 用于制备pde iv抑制剂的喹啉5－甲酰胺的合成
SE0302488D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab New combination
RU2006124843A (ru) 2003-12-12 2008-01-20 Уайт (Us) Хинолины, пригодные для лечения сердечно-сосудистого заболевания
CA2801848C (en) * 2003-12-26 2015-03-31 Masatoshi Hagiwara Methods for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity
GEP20084360B (en) * 2004-02-04 2008-04-29 Pfizer Prod Inc Substituted quinoline compounds
RU2411043C2 (ru) * 2004-04-01 2011-02-10 Юниверсите Де Льеж Фармацевтические композиции пиримидин-2,4,6-трионов
ATE531705T1 (de) * 2004-05-18 2011-11-15 Schering Corp Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren
ES2251866B1 (es) * 2004-06-18 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
ES2251867B1 (es) * 2004-06-21 2007-06-16 Laboratorios Almirall S.A. Nuevos derivados de piridazin-3(2h)-ona.
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
RS56037B1 (sr) 2004-06-24 2017-09-29 Vertex Pharma Modulatori atp-vezujućih kasetnih transportera
SA05260265A (ar) * 2004-08-30 2005-12-03 استرازينيكا ايه بي مركبات جديدة
MX2007004293A (es) * 2004-10-12 2007-06-18 Actelion Pharmaceuticals Ltd 1[2-(4-bencil-4-hidroxi-piperidin-1-il)-etil]-3-(2-metil-quinolin -4-il)-urea como la sal de sulfato cristalina.
MX2007004465A (es) * 2004-10-19 2007-05-07 Hoffmann La Roche Derivados de quinolina.
SE0402925D0 (sv) * 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
WO2007022946A1 (de) 2005-08-21 2007-03-01 Abbott Gmbh & Co. Kg Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
EP1928437A2 (en) 2005-08-26 2008-06-11 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP1940389A2 (en) 2005-10-21 2008-07-09 Braincells, Inc. Modulation of neurogenesis by pde inhibition
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
EP1979367A2 (en) * 2005-12-24 2008-10-15 Vertex Pharmaceuticals Incorporated Quinolin-4-one derivatives as modulators of abc transporters
EP3219705B1 (en) 2005-12-28 2020-03-11 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of the amorphous form of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
KR100821649B1 (ko) 2006-01-24 2008-04-11 서울시립대학교 산학협력단 클리오퀴놀을 유효성분으로 포함하는 ＨＩＦ-1α 활성제
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
KR20090026217A (ko) * 2006-07-11 2009-03-11 쉐링 코포레이션 치환된 5-옥사졸-2-일-퀴놀린 화합물의 크시나포에이트 염
JPWO2008026687A1 (ja) 2006-09-01 2010-01-21 杏林製薬株式会社 ピラゾロピリジンカルボキサミド誘導体及びそれらを含有するホスホジエステラーゼ（ｐｄｅ）阻害剤
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
CL2007003874A1 (es) * 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
ES2306595B1 (es) * 2007-02-09 2009-09-11 Laboratorios Almirall S.A. Sal de napadisilato de 5-(2-((6-(2,2-difluoro-2-feniletoxi)hexil)amino)-1-hidroxietil)-8-hidroxiquinolin-2(1h)-ona como agonista del receptor adrenergico beta2.
ES2320954B1 (es) * 2007-03-02 2010-03-16 Laboratorio Almirall S.A. Nuevo procedimiento de preparacion de 3-metil-4-fenilisoxazolo (3,4-d)iridazin-7(6h)-ona.
BRPI0809106A2 (pt) * 2007-03-22 2014-08-26 Astrazeneca Ab Derivados de quinolina para o tratamento de doenças inflamatórias
US9493419B2 (en) 2007-08-21 2016-11-15 The Hong Kong Polytechnic University Quinoline derivatives as anti-cancer agents
US9321730B2 (en) * 2007-08-21 2016-04-26 The Hong Kong Polytechnic University Method of making and administering quinoline derivatives as anti-cancer agents
US8106073B2 (en) 2007-11-30 2012-01-31 Astrazeneca Ab Quinoline derivatives 057
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
PL2408750T3 (pl) 2009-03-20 2016-02-29 Vertex Pharma Sposób otrzymywania modulatorów błonowego regulatora przewodnictwa swoistego dla mukowiscydozy
JP2011042643A (ja) * 2009-07-24 2011-03-03 Bayer Cropscience Ag 殺虫性カルボキサミド類
EP2569285A1 (en) 2010-05-10 2013-03-20 Gilead Sciences, Inc. Bifunctional quinoline derivatives
US8367829B2 (en) 2010-05-10 2013-02-05 Gilead Sciences, Inc. Bi-functional pyrazolopyridine compounds
EP2635280A4 (en) * 2010-11-05 2014-05-28 Univ Minnesota CYTOSINDEAMINASE MODULATORS TO IMPROVE DNA TRANSFECTION
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
WO2013106547A1 (en) 2012-01-10 2013-07-18 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
CN103254291B (zh) * 2013-05-30 2014-06-25 常州亚当生物技术有限公司 肿瘤坏死因子-α多肽抑制剂及其应用
CN103285373A (zh) * 2013-05-30 2013-09-11 苏州普罗达生物科技有限公司 肿瘤坏死因子-α多肽抑制剂制备及其应用
JP6223563B2 (ja) * 2013-10-14 2017-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物
CN107250113B (zh) 2014-10-07 2019-03-29 弗特克斯药品有限公司 囊性纤维化跨膜传导调节蛋白的调节剂的共晶
RU2624906C2 (ru) * 2015-12-22 2017-07-10 федеральное государственное бюджетное учреждение "Федеральный научно-исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Производные 2-хинальдинкарбоновой кислоты и их противогриппозная активность
WO2019053015A1 (en) 2017-09-13 2019-03-21 Syngenta Participations Ag MICROBIOCIDE DERIVATIVES OF QUINOLINE (THIO) CARBOXAMIDE
CN107812006A (zh) * 2017-11-13 2018-03-20 全椒先奇医药科技有限公司 一种治疗急性肾衰药物组合物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2517229A1 (de) * 1975-04-18 1976-10-28 Boehringer Mannheim Gmbh Phenylalkylcarbonsaeure-derivate und verfahren zu ihrer herstellung
US4186201A (en) * 1977-02-07 1980-01-29 Riker Laboratories, Inc. Methods of using 8(tetrazol-5-ylcarbamoyl)isoquinoline compounds
US4147694A (en) * 1977-02-07 1979-04-03 Riker Laboratories, Inc. 8-(1H-Tetrazol-5-yl-carbamoyl)quinoline compounds
WO1986006721A1 (en) * 1985-05-07 1986-11-20 Alkaloida Vegyészeti Gyár Triazolyl quinoline derivatives
EP0498722B1 (fr) * 1991-02-07 1997-07-30 Roussel Uclaf Dérivés bicycliques azotés, leur procédé de préparation, les intermédiaires obtenus, leur application comme médicaments et les compositions pharmaceutiques les renfermant
US5455252A (en) * 1993-03-31 1995-10-03 Syntex (U.S.A.) Inc. Optionally substituted 6,8-quinolines
SE9302490D0 (sv) * 1993-07-26 1993-07-26 Kabi Pharmacia Ab New use of old drugs

Also Published As

Publication number Publication date
CZ365198A3 (cs) 1999-03-17
EP0952832A1 (en) 1999-11-03
NO985376D0 (no) 1998-11-19
WO1997044036A1 (en) 1997-11-27
EP0952832B1 (en) 2008-08-27
TR199802385T2 (xx) 1999-04-21
ATE406163T1 (de) 2008-09-15
CN1219131A (zh) 1999-06-09
NO312099B1 (no) 2002-03-18
CZ296163B6 (cs) 2006-01-11
NZ332341A (en) 2000-05-26
IL126557A0 (en) 1999-08-17
AU2905897A (en) 1997-12-09
RU2170730C2 (ru) 2001-07-20
JP2000510865A (ja) 2000-08-22
CA2252531A1 (en) 1997-11-27
SK160598A3 (en) 1999-12-10
KR20000065219A (ko) 2000-11-06
DE69738949D1 (de) 2008-10-09
IL126557A (en) 2002-09-12
AU722472B2 (en) 2000-08-03
NO985376L (no) 1998-11-19
BR9709015A (pt) 1999-08-03
US5804588A (en) 1998-09-08
PL329922A1 (en) 1999-04-26
SK283162B6 (sk) 2003-03-04

Similar Documents

Publication Publication Date Title
CN1148189C (zh) 作为tnf抑制剂和pdc-iv抑制剂的喹啉甲酰胺类化合物
CN1260225C (zh) 四氢吡啶基或哌啶基杂环衍生物
CN1263755C (zh) 作为选择性cox－2抑制剂的吡唑并吡啶衍生物
CN100338061C (zh) 炔－芳基磷酸二酯酶－4抑制剂
CN1046725C (zh) 稠合的咪唑化合物,它们的制备和应用
CN1118464C (zh) 新颖嘧啶衍生物及其制法
CN1337950A (zh) 2－氧代喹啉化合物及其药物用途
CN1906189A (zh) 用于治疗呼吸系统疾病的1－乙酸－吲哚、－吲唑和－苯并咪唑衍生物
CN1094028A (zh) 选择性的磷酸二酯酶(ⅳ)抑制剂儿茶酚二醚类
CN1906190A (zh) 选择性激酶抑制剂
CN1665789A (zh) 二氨基嘧啶酰胺衍生物
CN1221544C (zh) 吡唑环腺苷酸－特异性磷酸二酯酶抑制剂
CN1310621A (zh) 取代的n－酰苯胺化合物和方法
CN1468216A (zh) 含氮五员环化合物
CN1033380A (zh) 化合物
CN1127486C (zh) 二氮杂萘衍生物磷酸二酯酶4抑制剂
CN1039323C (zh) 咪唑并吡啶衍生物的制备方法
CN1202171A (zh) 吡啶并[2,3－d]嘧啶衍生物及其医药组合物
CN1027368C (zh) 新型取代的喹啉衍生物的制备方法
CN1086819A (zh) 有5-羟色胺受体拮抗活性的新化合物
CN1503797A (zh) 吡啶并嘧啶或二氮杂萘衍生物
CN1802367A (zh) 作为谷氨酸受体拮抗剂的咪唑衍生物
CN1067072C (zh) 三环化合物、它们的制备及其用途
CN1993358A (zh) 作为趋化因子受体拮抗剂的噻唑衍生物
CN1085550A (zh) 作为人类免疫缺乏病毒逆转录酶抑制剂的新的喹唑啉类

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee